Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | NCF1 | P14598 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CYBB | P04839 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848335 | 0.85 | NCF1 (0.32) | BACE1NCF1NOS2KDM4EALDH1A1 | |
| SCHEMBL4843280 | 0.77 | BCHE (0.30) | — | |
| SCHEMBL7972525 | 0.77 | CYP1A2 (0.41) | NCF1ALDH1A1 | |
| SCHEMBL7976285 | 0.77 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL1789932 | 0.74 | NPC1 (0.46) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL27999697 | 0.70 | ALDH1A1 (0.52) | BACE1NCF1NOS2KDM4EALDH1A1 | |
| SCHEMBL29447182 | 0.70 | ALDH1A1 (0.52) | BACE1NCF1NOS2KDM4EALDH1A1 | |
| SCHEMBL462847 | 0.70 | ALDH1A1 (0.52) | BACE1NCF1NOS2KDM4EALDH1A1 | |
| SCHEMBL16223776 | 0.69 | ALDH1A1 (0.36) | KDM4EALDH1A1MAPTHSD17B10PDPK1 | |
| Bromide SCHEMBL7244276 | 0.69 | ALDH1A1 (0.50) | BACE1NCF1NOS2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1780211-A2 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1775295-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | BACE1 1242/4885NCF1 2882/4885NOS2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.